Last month, the European Medicines Agency’s scientific advisory panel, the Committee for Medicinal Products for Human Use (CHMP), issued a positive recommendation for the marketing authorization of GSK plc’s oral drug candidate Jesduvroq (daprodustat) to treat adults with symptomatic anemia with chronic kidney disease (CKD) on dialysis. (Also see "EU CHMP Opinions And MAA Updates" - Pink Sheet, 26 June, 2023.).
GSK Pulls EU Filing For Jesduvroq In CKD Anemia After Label Narrowed
GSK’s Jesduvroq was set for imminent EU approval to treat anemia in patients with chronic kidney disease receiving dialysis, but the firm has withdrawn its marketing authorization application after the EMA recommended excluding non-dialysis patients from the label.
More from Europe
• By
Cell and gene therapy manufacturers must consider the practicalities of their product within the context of a health care system before it comes onto the market to be successful, experts from Novartis, AstraZeneca and England’s National Health Service say.
• By
Novartis is planning to file EU and US marketing applications for an intrathecal formulation of its spinal muscular atrophy gene therapy, Zolgensma, in H1 2025.
• By
Sponsors of three drugs that are in the final stages of the EU regulatory review cycle are due to make the case for marketing approval before the European Medicines Agency.
• By
Experts working in the advanced therapy space say the US has less strict criteria for regulatory pathways for cell and gene therapies than the EU, particularly for products in early development.
More from Geography
• By
A global collaborative inspections pilot reduced the number of individual inspections for participating manufacturing facilities, demonstrating that multiple regulatory authorities can carry out joint inspections using a mix of on-site and remote approaches.
• By
Novartis is planning to file EU and US marketing applications for an intrathecal formulation of its spinal muscular atrophy gene therapy, Zolgensma, in H1 2025.
• By
A new annual report from China's CDE shows a rise in overall product approvals but a fall in the transition rate for conditional to full approvals, possibly signalling more stringent requirements.